NICE in the UK has published a final guidance on recommendation for use of icosapent ethyl in adult statin-treated patients with elevated triglycerides, well-controlled LDL-c and established CVD.

A network meta-analysis shows both PCSK9i and ezetimibe may reduce non-fatal MI and stroke in adults on maximum statin therapy or with statin intolerance who are at very high or high CVD risk but not in those at moderate or low risk.

Prolonged sitting is related to mortality and CVD in high-income countries. Whether this is also true for low- and middle-income countries was investigated in a study using data from the Prospective Urban Rural Epidemiology (PURE) study.

The National Lipid Association (NLA) has published a new scientific statement on statin intolerance, which includes a new definition and key consideration for ASCVD risk reduction in patients who are statin intolerant.

DOACs such as apixaban and rivaroxaban are increasingly prescribed to patients with VTE, but the results of trials directly comparing these agents are not available. What can we conclude from a retrospective cohort study?

A difference between the DOACs apixaban and rivaroxaban is that apixaban is taken twice daily, whereas a single daily dose is sufficient for rivaroxaban. How do the efficacy and safety of both anticoagulants compare in patients with AF?

The causal effect of LDL-c on CVD risk was stronger in male than in female participants of the UK Biobank cohort, suggesting that LDL‐c is a less important predictor of CVD risk in women than in men.

In a subanalysis of the ODYSSEY OUTCOMES trial, 95% of patients with recent acute coronary syndrome (ACS) achieved LDL-c <1.4 mmol/L when alirocumab was added to optimal statin therapy, instead of only 17% with placebo.

In a large cohort of AF patients, new brain infarcts occurred frequently, despite a high anticoagulation rate. Both clinically overt and silent brain infarcts were associated with cognitive decline.

Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.

Smoking is an important modifiable risk factor for HF. But to what extent does this apply to the 2 phenotypes of HF: HFrEF and HFpEF? And what is the effect of (long-term) smoking cessation? A recent analysis of the ARIC study offers valuable insights.

Tirzepatide has an agonistic effect not only on the GLP-1 receptor, but also on the glucose-dependent insulinotropic polypeptide (GIP) receptor. Whether this leads to substantial weight reduction in obese individuals without T2DM was investigated in the SURMOUNT-1 trial.